OncoImmunology (Jan 2018)

TIGIT expressing CD4+T cells represent a tumor-supportive T cell subset in chronic lymphocytic leukemia

  • Kemal Catakovic,
  • Franz Josef Gassner,
  • Christoph Ratswohl,
  • Nadja Zaborsky,
  • Stefan Rebhandl,
  • Maria Schubert,
  • Markus Steiner,
  • Julia Christine Gutjahr,
  • Lisa Pleyer,
  • Alexander Egle,
  • Tanja Nicole Hartmann,
  • Richard Greil,
  • Roland Geisberger

DOI
https://doi.org/10.1080/2162402X.2017.1371399
Journal volume & issue
Vol. 7, no. 1

Abstract

Read online

While research on T cell exhaustion in context of cancer particularly focuses on CD8+ cytotoxic T cells, the role of inhibitory receptors on CD4+ T-helper cells have remained largely unexplored. TIGIT is a recently identified inhibitory receptor on T cells and natural killer (NK) cells. In this study, we examined TIGIT expression on T cell subsets from CLL patients. While we did not observe any differences in TIGIT expression in CD8+ T cells of healthy controls and CLL cells, we found an enrichment of TIGIT+ T cells in the CD4+ T cell compartment in CLL. Intriguingly, CLL patients with an advanced disease stage displayed elevated numbers of CD4+ TIGIT+ T cells compared to low risk patients. Autologous CLL-T cell co-culture assays revealed that depleting CD4+ TIGIT+ expressing T cells from co-cultures significantly decreased CLL viability. Accordingly, a supportive effect of TIGIT+CD4+ T cells on CLL cells in vitro could be recapitulated by blocking the interaction of TIGIT with its ligands using TIGIT-Fc molecules, which also impeded the T cell specific production of CLL-prosurvival cytokines. Our data reveal that TIGIT+CD4+T cells provide a supportive microenvironment for CLL cells, representing a potential therapeutic target for CLL treatment.

Keywords